Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. / Alzheimer Disease Neuroimaging Initiative; AIBL Research Group; ICTUS/DSA study groups.

I: Alzheimer's and Dementia, Bind 15, Nr. 7, 07.2019, s. 888-898.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Alzheimer Disease Neuroimaging Initiative, AIBL Research Group & ICTUS/DSA study groups 2019, 'Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype', Alzheimer's and Dementia, bind 15, nr. 7, s. 888-898. https://doi.org/10.1016/j.jalz.2019.04.001

APA

Alzheimer Disease Neuroimaging Initiative, AIBL Research Group, & ICTUS/DSA study groups (2019). Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimer's and Dementia, 15(7), 888-898. https://doi.org/10.1016/j.jalz.2019.04.001

Vancouver

Alzheimer Disease Neuroimaging Initiative, AIBL Research Group, ICTUS/DSA study groups. Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. Alzheimer's and Dementia. 2019 jul.;15(7):888-898. https://doi.org/10.1016/j.jalz.2019.04.001

Author

Alzheimer Disease Neuroimaging Initiative ; AIBL Research Group ; ICTUS/DSA study groups. / Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype. I: Alzheimer's and Dementia. 2019 ; Bind 15, Nr. 7. s. 888-898.

Bibtex

@article{f7eab8b0b7854daf809a1ba5b9bc2ecc,
title = "Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype",
abstract = "Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. Methods: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. Results: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. Discussion: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.",
keywords = "Alzheimer's disease, APOE, Clinical setting, Dementia, Disease duration, Multistate model, Preclinical, Prodromal, Progression",
author = "Lisa Vermunt and Sikkes, {Sietske A.M.} and {van den Hout}, Ardo and Ron Handels and Isabelle Bos and {van der Flier}, {Wiesje M.} and Silke Kern and Ousset, {Pierre Jean} and Paul Maruff and Ingmar Skoog and Verhey, {Frans R.J.} and Yvonne Freund-Levi and Magda Tsolaki and Wallin, {{\AA}sa K.} and Olde-Rikkert, {M. G.M.} and Hilkka Soininen and Luisa Spiru and Henrik Zetterberg and Kaj Blennow and Philip Scheltens and Graciela Muniz-Terrera and Visser, {Pieter Jelle} and {Alzheimer Disease Neuroimaging Initiative} and {AIBL Research Group} and {ICTUS/DSA study groups} and B. Vellas and E. Reynish and Ousset, {P. J.} and S. Andrieu and A. Burns and F. Pasquier and G. Frisoni and E. Salmon and Michel, {J. P.} and Zekry, {D. S.} and M. Boada and Dartigues, {J. F.} and Olde-Rikkert, {M. G.M.} and Rigaud, {A. S.} and B. Winblad and A. Malick and A. Sinclair and L. Fr{\"o}lich and P. Scheltens and C. Ribera and J. Touchon and P. Robert and A. Salva and G. Waldemar and R. Bullock and M. Tsolaki and G. Rodriguez and L. Spiru",
year = "2019",
month = jul,
doi = "10.1016/j.jalz.2019.04.001",
language = "English",
volume = "15",
pages = "888--898",
journal = "Alzheimer's & Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "7",

}

RIS

TY - JOUR

T1 - Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype

AU - Vermunt, Lisa

AU - Sikkes, Sietske A.M.

AU - van den Hout, Ardo

AU - Handels, Ron

AU - Bos, Isabelle

AU - van der Flier, Wiesje M.

AU - Kern, Silke

AU - Ousset, Pierre Jean

AU - Maruff, Paul

AU - Skoog, Ingmar

AU - Verhey, Frans R.J.

AU - Freund-Levi, Yvonne

AU - Tsolaki, Magda

AU - Wallin, Åsa K.

AU - Olde-Rikkert, M. G.M.

AU - Soininen, Hilkka

AU - Spiru, Luisa

AU - Zetterberg, Henrik

AU - Blennow, Kaj

AU - Scheltens, Philip

AU - Muniz-Terrera, Graciela

AU - Visser, Pieter Jelle

AU - Alzheimer Disease Neuroimaging Initiative

AU - AIBL Research Group

AU - ICTUS/DSA study groups

AU - Vellas, B.

AU - Reynish, E.

AU - Ousset, P. J.

AU - Andrieu, S.

AU - Burns, A.

AU - Pasquier, F.

AU - Frisoni, G.

AU - Salmon, E.

AU - Michel, J. P.

AU - Zekry, D. S.

AU - Boada, M.

AU - Dartigues, J. F.

AU - Olde-Rikkert, M. G.M.

AU - Rigaud, A. S.

AU - Winblad, B.

AU - Malick, A.

AU - Sinclair, A.

AU - Frölich, L.

AU - Scheltens, P.

AU - Ribera, C.

AU - Touchon, J.

AU - Robert, P.

AU - Salva, A.

AU - Waldemar, G.

AU - Bullock, R.

AU - Tsolaki, M.

AU - Rodriguez, G.

AU - Spiru, L.

PY - 2019/7

Y1 - 2019/7

N2 - Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. Methods: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. Results: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. Discussion: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.

AB - Introduction: We estimated the age-specific duration of the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD) and the influence of sex, setting, apolipoprotein E (APOE) genotype, and cerebrospinal fluid tau on disease duration. Methods: We performed multistate modeling in a combined sample of 6 cohorts (n = 3268) with death as the end stage and estimated the preclinical, prodromal, and dementia stage duration. Results: The overall AD duration varied between 24 years (age 60) and 15 years (age 80). For individuals presenting with preclinical AD, age 70, the estimated preclinical AD duration was 10 years, prodromal AD 4 years, and dementia 6 years. Male sex, clinical setting, APOE ε4 allele carriership, and abnormal cerebrospinal fluid tau were associated with a shorter duration, and these effects depended on disease stage. Discussion: Estimates of AD disease duration become more accurate if age, sex, setting, APOE, and cerebrospinal fluid tau are taken into account. This will be relevant for clinical practice and trial design.

KW - Alzheimer's disease

KW - APOE

KW - Clinical setting

KW - Dementia

KW - Disease duration

KW - Multistate model

KW - Preclinical

KW - Prodromal

KW - Progression

U2 - 10.1016/j.jalz.2019.04.001

DO - 10.1016/j.jalz.2019.04.001

M3 - Journal article

C2 - 31164314

AN - SCOPUS:85066298869

VL - 15

SP - 888

EP - 898

JO - Alzheimer's & Dementia

JF - Alzheimer's & Dementia

SN - 1552-5260

IS - 7

ER -

ID: 241827591